CANCER RESEARCH AND BIOSTATISTICS

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1997

Legal Domicile

Principal Officer

DAMIEN MAR CHONG

Phone

2068391710

Tax Period

2023-01-01 to 2023-12-31

CANCER RESEARCH AND BIOSTATISTICS, founded in 1997, is a mid-sized nonprofit in the Medical Research sector that reported $12.1M in total revenue in fiscal year 2023.

Mission

TO HELP CONQUER CANCER AND OTHER DISEASES THROUGH THE APPLICATION OF BIOSTATISTICAL PRINCIPLES AND INNOVATIVE DATA MANAGEMENT METHODS.

Program Service Accomplishments

Program 1

Expenses: $8,774,912 Revenue: $3,397,062

CANCER RESEARCH & BIOSTATISTICS (CRAB) IS A NATIONAL LEADER IN DESIGNING AND MANAGING ONCOLOGY CLINICAL TRIALS. CRAB IS THE STATISTICAL CENTER FOR SWOG (THE LARGEST NCI COOPERATIVE GROUP). IT IS...

CANCER RESEARCH & BIOSTATISTICS (CRAB) IS A NATIONAL LEADER IN DESIGNING AND MANAGING ONCOLOGY CLINICAL TRIALS. CRAB IS THE STATISTICAL CENTER FOR SWOG (THE LARGEST NCI COOPERATIVE GROUP). IT IS CRAB'S GOAL TO PROVIDE SUPPORT AND STATISTICAL CONSULTATION FOR STUDY DESIGN, PROTOCOL DEVELOPMENT, RESEARCH DATA ANALYSIS, MANUSCRIPT WRITING, AND PRESENTATIONS AT MAJOR CONFERENCES IN ONCOLOGY RESEARCH. CRAB VALUES THE LONG-STANDING RELATIONSHIPS THAT IT HAS WITH ORGANIZATIONS TO WORK, SUPPORT AND DISCOVER NEW AND IMPROVED TREATMENTS FOR CANCER PATIENTS AND CONTINUES TO MAKE RESEARCH ALLIANCES WITH LEADING RESEARCH CONSORTIA, CANCER CENTERS, AND INDUSTRY. CRAB IS THE LEADER OF THE PANCREATIC CANCER RESEARCH TEAM (PCRT), A CONSORTIUM OF MORE THAN 40 CLINICS WORLDWIDE ESTABLISHED FOR BIOTECH AND PHARMACEUTICAL COMPANIES LOOKING TO DEVELOP NEW AGENTS FOR PATIENTS WITH PANCREAS CANCER.

Program 2

Expenses: $26,797 Revenue: $28,014

IN 2023, CRAB CONTINUED TO PROVIDE ONGOING SUPPORT THROUGH EXCELLENT TRAINING TO EARLY CAREER INVESTIGATORS AND CLINICAL RESEARCH ASSOCIATES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $8,475,824

Program Service Revenue $3,425,076

Investment Income $182,441

Other Revenue $0

TOTAL REVENUE $12,083,341

Expense Breakdown

Grants Paid $0

Salaries & Benefits $9,431,379

Fundraising Expenses $0

Program Expenses $8,801,709

Other Expenses $3,096,470

TOTAL EXPENSES $12,527,849

Year-over-Year Comparison

	2023	2022	Change
Revenue	$12,083,341	$12,214,852	0.0%
Expenses	$12,527,849	$12,123,661	+0.0%
Net Income	$-444,508	$91,191	-5.9%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,096,104

Total Directors

$501,636

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
HOERING ANTJE	CEO & BOARD PRESIDENT	40.00	Officer Director	$378,488	$38,308	$416,796
CROWLEY JOHN J	DIRECTOR/CHIEF OF STRATEGIC ALLIANCES	16.00	Director	$84,840	$0	$84,840
DAVIS RODERIC	DIRECTOR	0.00	Director	$0	$0	$0
HEAGERTY PATRICK	DIRECTOR	0.00	Director	$0	$0	$0
CURCI FRANK	DIRECTOR	0.00	Director	$0	$0	$0
GOODMAN GARY	DIRECTOR	0.00	Director	$0	$0	$0
GRAY DAVID	DIRECTOR	0.00	Director	$0	$0	$0
LEBLANC MICHAEL	DIRECTOR	0.00	Director	$0	$0	$0
CUMMINS TIM	DIRECTOR	0.00	Director	$0	$0	$0
SNAPINN STEVE	DIRECTOR	0.00	Director	$0	$0	$0
ALVENDIA MELISSA	DIRECTOR	0.00	Director	$0	$0	$0
ROSS ARTHUR	DIRECTOR	0.00	Director	$0	$0	$0
SHAM JONATHAN	DIRECTOR	0.00	Director	$0	$0	$0
MALLOY CURT	VP, COO & BOARD SECRETARY	40.00	Officer	$221,445	$28,014	$249,459
COOK CHRIS	VP, CHIEF TECHNOLOGY OFFICER	40.00	Officer	$198,488	$23,618	$222,106
MAR CHONG DAMIEN	VP, CFO & BOARD TREASURER	40.00	Officer	$184,799	$22,944	$207,743
DURHAM PATRICK G	DIRECTOR OF IT	40.00	Highest	$174,103	$22,034	$196,137
NISHIMURA KATHERINE K	SENIOR BIOSTATISTICIAN	40.00	Highest	$172,007	$21,152	$193,159
MILLER BRIAN	DIRECTOR OF FINANCE	40.00	Highest	$166,668	$17,995	$184,663
SUTTER RODNEY	PROGRAM DIRECTOR, THERAPEUTIC STUDIES	40.00	Highest	$141,166	$19,773	$160,939
BARLOW WILLIAM E	SENIOR BIOSTATISTICIAN	24.00	Highest	$144,217	$19,231	$163,448

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$12,083,341	$12,527,849	$11,524,760	$-444,508
2022	$12,214,852	$12,123,661	$12,381,610	$91,191
2021	$11,626,712	$11,787,377	$8,442,496	$-160,665
2020	$12,617,095	$11,280,432	$8,761,603	$1,336,663
2019	$12,787,003	$12,197,319	$7,388,278	$589,684
2018	$13,151,469	$12,750,418	$7,935,812	$401,051